Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
Retrieved on:
Thursday, August 4, 2022
Biotechnology, General Health, Health, Master of Laws, Medicine, Johnson & Johnson, MD Anderson Cancer Center, Senior, Business development, Schering-Plough, Leadership, History of the University of Maryland, College Park, NK, Board, Director, Research, International law, Patient, GenScript Biotech, Nasdaq, Therapy, Company, Doctor of Philosophy, Nanjing Medical University, 19th Presidential Awards, Nanjing University, NASDAQ, Sino Biopharmaceutical Limited, Shenzhen Stock Exchange, Immunotherapy, Biochemistry, Goal, University, University of Antwerp, Time, Duke University, Chair, Capital Group Companies, Management, Pharmaceutical industry
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang Frank Zhang as Class II director of Legend Biotech, and Dr. Li Mao as Class III director of Legend Biotech.
Key Points:
- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang Frank Zhang as Class II director of Legend Biotech, and Dr. Li Mao as Class III director of Legend Biotech.
- Dr. Frank Zhang, one of the newly appointed directors, was elected Chairman of the Board of Directors.
- Both the size and composition of the Board have been under evaluation for some time.
- We look forward to her many future contributions as she remains a strong asset to our Board.